Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-03-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
内部控制审计报告
Regulatory Filings
2020-03-30 Chinese
2019年度审计与风险控制委员会履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2019年度审计与风险控制委员会履职报告" which translates to the "2019 Annual Audit and Risk Control Committee Performance Report". It details the activities, meetings, and evaluations of the Audit and Risk Control Committee for the year 2019, including their oversight of the 2018 annual audit and internal controls. The document is a report on the committee's duties and findings rather than a full annual report or standalone audit report. It is not a financial statement or a direct audit report but a committee's performance report related to audit and risk control. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related committee reports on audit and risk control activities. The document length is 2347 characters, which is sufficient for a detailed committee report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2019
2020-03-30 Chinese
九届二十五次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 25th meeting of the 9th Board of Directors of Kunming Pharmaceutical Group Co., Ltd. It includes voting results on various company matters such as the 2019 annual board work report, independent director reports, audit and risk control committee reports, internal control reports, financial statements, profit distribution plans, social responsibility reports, and other operational and governance issues. The document also references multiple related announcements and reports published on the Shanghai Stock Exchange website. The content is focused on board decisions and approvals rather than the full text of any financial or annual report. It is not a full annual report (10-K), nor a management discussion, nor a call transcript. It is not a simple announcement of a report publication but a formal record of board resolutions. Therefore, the document fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The confidence in this classification is high given the detailed nature of board resolutions and voting results presented.
2020-03-30 Chinese
关于追加公司2019年与控股股东日常关联交易额度的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the increase in the 2019 daily related-party transaction quota with its controlling shareholder. It details the nature of the related-party transactions, the approval process by the board and supervisory committee, the parties involved, and the pricing policies. The document is a formal disclosure of a corporate transaction related to related-party dealings, not a financial report or earnings release. It does not contain financial statements or management discussion of results, nor is it a report publication announcement. The content fits the category of a regulatory announcement about related-party transactions, which is best classified under Regulatory Filings (RNS) as it does not fit other more specific categories like Capital/Financing Update or Management Reports. The document length is about 4856 characters, which is consistent with a detailed announcement rather than a full report.
2020-03-30 Chinese
关于2020年度担保计划的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the 2020 annual guarantee plan of Kunming Pharmaceutical Group Co., Ltd. It includes specifics about the guarantee amounts, the companies involved, their financial status as of December 31, 2019, and the board and independent directors' opinions on the guarantee plan. The document is not a full financial report but rather a disclosure about the company's guarantee commitments and related internal approvals. It does not contain comprehensive financial statements or quarterly results but focuses on the guarantee plan and related corporate governance matters. This type of document fits best under the category of a Regulatory Filing (RNS), as it is a regulatory announcement about the company's guarantee plan and related disclosures, not a full annual report, interim report, or other specific financial report type.
2020-03-30 Chinese
北京德恒（昆明）律师事务所关于昆药集团股份有限公司回购注销2017年限制性股票激励计划部分限制性股票的法律意见
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the repurchase and cancellation of restricted shares under a 2017 stock incentive plan by Kunming Pharmaceutical Group Co., Ltd. It details the legal compliance, procedures, reasons, quantities, prices, and effects on share capital structure related to the repurchase and cancellation of restricted stock. The document is not a financial report, earnings release, or management discussion but a legal opinion related to a specific corporate action involving share repurchase and cancellation. This fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares, including share repurchase and cancellation activities. The document length is 4200 characters, which is relatively short but contains substantive legal opinion and details about the transaction, not merely an announcement or certification. Therefore, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2020-03-30 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.